Literature DB >> 16133484

Effects of ionic and non-ionic paramagnetic contrast media on brain bio-electric activity.

A Messori1, G Polonara, L Regnicolo, L Provinciali, M Signorino, U Salvolini.   

Abstract

The potential neurotoxic effects of gadolinium (Gd)-based compounds for enhanced MRI are not completely understood. We investigated electroencephalography changes induced by ionic and non-ionic Gd-based compounds administered intravenously in patients affected by lesions of the central nervous system (CNS) characterized by breakdown of the blood-brain barrier. This double-blind, randomized, study of two parallel groups involved 40 patients scheduled for an MRI examination with contrast medium for known CNS lesions. Twenty patients were randomly allocated to receive non-ionic Gd-DTPA-BMA/gadodiamide and 20 patients were randomly allocated to receive ionic Gd-DTPA/gadopentetate. For both groups the intravenous dose was 0.1 mmol/kg body weight. Three electroencephalography recordings were performed: immediately before, during, and 15 min after contrast medium injection. Mean and peak frequencies of the beta band and absolute power of the delta and/or theta bands of the electroencephalograms (EEGs) were noted. Each EEG was also evaluated to detect any alterations. The values of the 8-12 Hz band showed a significant increase during and after injection versus baseline in the gadopentetate group (P<0.05) and a significant decrease during injection in the gadodiamide group (P<0.05). The values of the 12-16 Hz band showed a significant increase versus baseline during and after injection in the gadopentetate group (P<0.05). The electrophysiological method based on computerised spectral analysis is a sensitive tool for evaluating effects of contrast media on brain bio-electric activity. EEG changes are detectable, even in the absence of any clinical evidence. It would appear that there might be clinical advantages in the use of non-ionic compounds.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133484     DOI: 10.1007/s00234-005-1429-x

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  25 in total

1.  Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine.

Authors:  D Balériaux; C Colosimo; J Ruscalleda; M Korves; G Schneider; K Bohndorf; G Bongartz; M A van Buchem; M Reiser; K Sartor; M W Bourne; P M Parizel; G R Cherryman; I Salerio; A La Noce; G Pirovano; M A Kirchin; A Spinazzi
Journal:  Neuroradiology       Date:  2002-03       Impact factor: 2.804

2.  Neurotoxic effects of gadopentetate dimeglumine: behavioral disturbance and morphology after intracerebroventricular injection in rats.

Authors:  D E Ray; J B Cavanagh; C C Nolan; S C Williams
Journal:  AJNR Am J Neuroradiol       Date:  1996-02       Impact factor: 3.825

3.  Generalized seizure after i.v. administration of gadopentetate dimeglumine.

Authors:  O L Harbury
Journal:  AJNR Am J Neuroradiol       Date:  1991 Jul-Aug       Impact factor: 3.825

Review 4.  In vitro and animal experiments in contrast media testing.

Authors:  W Krause
Journal:  Invest Radiol       Date:  1998-03       Impact factor: 6.016

5.  Contrast agent overdose causing brain retention of contrast, seizures and parkinsonism.

Authors:  E F May; G S Ling; C A Geyer; B Jabbari
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

6.  A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology.

Authors:  V M Runge; M R Armstrong; R G Barr; B L Berger; L F Czervionke; C F Gonzalez; H H Halford; E Kanal; M J Kuhn; J M Levin; R N Low; L N Tanenbaum; A M Wang; W Wong; W T Yuh; G H Zoarski
Journal:  Invest Radiol       Date:  2001-02       Impact factor: 6.016

7.  MRI in children given gadodiamide injection: safety and efficacy in CNS and body indications.

Authors:  B Lundby; P Gordon; F Hugo
Journal:  Eur J Radiol       Date:  1996-11       Impact factor: 3.528

8.  Nonconvulsive status epilepticus after intravenous contrast medium administration.

Authors:  T G Lukovits; C E Fadul; J M Pipas; P D Williamson
Journal:  Epilepsia       Date:  1996-11       Impact factor: 5.864

9.  MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals.

Authors:  Francois Cotton; Howard L Weiner; Ferenc A Jolesz; Charles R G Guttmann
Journal:  Neurology       Date:  2003-02-25       Impact factor: 9.910

10.  Neurotoxic potential of gadodiamide after injection into the lateral cerebral ventricle of rats.

Authors:  D E Ray; J L Holton; C C Nolan; J B Cavanagh; E S Harpur
Journal:  AJNR Am J Neuroradiol       Date:  1998-09       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.